Syros Pharmaceuticals, a leader in the development of medicines that control the expression of genes, announced the grant of restricted stock unit awards for an aggregate of 8,200 shares of Syros common stock to two newly hired employees in connection with their commencement of employment with Syros.
September 2, 2022
· 1 min read